MétaCan
Menu
Back to cohort
Record W2987590359 · doi:10.1016/j.chest.2019.10.043

Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents

2019· review· en· W2987590359 on OpenAlexaff
Vallerie V. McLaughlin, Richard N. Channick, Teresa De Marco, Harrison W. Farber, Seán Gaine, Nazzareno Galiè, Richard A. Krasuski, Ioana R. Preston, Rogério Souza, Gerry Coghlan, Robert P. Frantz, Anna R. Hemnes, Nick H. Kim, Iréne Lang, David Langleben, Mengtao Li, Olivier Sitbon, Victor F. Tapson, Adaani Frost

Bibliographic record

VenueCHEST Journal · 2019
Typereview
Languageen
FieldMedicine
TopicPulmonary Hypertension Research and Treatments
Canadian institutionsJewish General HospitalMcGill University
FundersActelion PharmaceuticalsSchool of Dental Medicine, University of PittsburghSt. Jude MedicalCardiovascular Medical Research and Education FundBayer FundAcceleronUniversity of MichiganUnited Therapeutics CorporationMeso Scale DiagnosticsGlaxoSmithKlineNovartisPfizerBoehringer IngelheimEdwards LifesciencesBristol-Myers SquibbGilead SciencesNational Institutes of HealthMedtronic
KeywordsMedicineTreprostinilIntensive care medicineAmbrisentanProstacyclinMEDLINEEndothelin receptor antagonistPopulationClinical trialPulmonary hypertensionInternal medicineCardiologyBosentanEndothelin receptor

Abstract

fetched live from OpenAlex

BACKGROUND: Treatment of pulmonary arterial hypertension (PAH) has evolved substantially over the past two decades and varies according to etiology, functional class (FC), hemodynamic parameters, and other clinical factors. Current guidelines do not provide definitive recommendations regarding the use of oral prostacyclin pathway agents (PPAs) in PAH. To provide guidance on the use of these agents, an expert panel was convened to develop consensus statements for the initiation of oral PPAs in adults with PAH. METHODS: A systematic literature search was conducted using MEDLINE. The established RAND/University of California Los Angeles appropriateness method, which incorporates the Delphi method and the nominal group technique, was used to create consensus statements. Idiopathic, heritable, repaired congenital heart defect, and drug- or toxin-induced PAH (IPAH+) was considered as one etiologic grouping. The process was focused on the use of oral treprostinil or selexipag in patients with IPAH+ or connective tissue disease-associated PAH and FC II or III symptoms receiving background dual endothelin receptor antagonist/phosphodiesterase type 5 inhibitor therapy. RESULTS: The panel developed 14 consensus statements regarding the appropriate use of oral PPAs in the target population. The panel identified 13 clinical scenarios in which selexipag may be considered as a treatment option. CONCLUSIONS: The paucity of clinical evidence overall, and particularly from randomized trials in this setting, creates a gap in knowledge. These consensus statements are intended to aid physicians in navigating treatment options and using oral PPAs in the most appropriate manner in patients with PAH.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.226
metaresearch head score (Gemma)0.395
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.226
Threshold uncertainty score0.955

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.2260.395
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0030.004
Bibliometrics0.0130.011
Science and technology studies0.0020.002
Scholarly communication0.0040.004
Open science0.0020.006
Research integrity0.0030.002
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.236
GPT teacher head0.383
Teacher spread0.147 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations47
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueCHEST JournalSame topicPulmonary Hypertension Research and TreatmentsFrench-language works237,207